Does p53 status influence tumor response to anticancer therapies?

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Anti-Cancer Drugs

• Publication date

  2000-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00001813-200007000-00002PMID 11001382
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?

  2004cited by this paper
• Signaling networks and cell cycle control : the molecular basis of cancer and other diseases

  2000cited by this paper
• Transferrin-Liposome-Mediated Systemic p53 Gene Therapy in Combination with Radiation Results in Regression of Human Head and Neck Cancer Xenografts

  1999cited by this paper
• Apoptosis, p53, and tumor cell sensitivity to anticancer agents.

  1999cited by this paper
• Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.

  1999cited by this paper
• Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy.

  1999cited by this paper
• Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

  1999cited by this paper
• The p53 pathway

  1999cited by this paper
• Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy.

  1999cited by this paper
• p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors.

  1999cited by this paper
• p53 protein accumulation as a prognostic marker of preoperative radiotherapy and/or chemotherapy in advanced squamous cell esophageal carcinoma - preliminary report.

  1999cited by this paper
• The dual role model for p53 in maintaining genomic integrity

  1999cited by this paper
• Mechanisms of p53-mediated apoptosis

  1999cited by this paper
• Overexpression of p53 protein associates decreased response to chemoradiotherapy in patients with esophageal carcinoma.

  1999cited by this paper
• p53-oriented cancer therapies: current progress.

  1999cited by this paper
• Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene.

  1999cited by this paper
• BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.

  1999cited by this paper
• Combined radiation and p53 gene therapy of malignant glioma cells

  1999cited by this paper
• Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal

  1999cited by this paper
• bcl-2 immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma

  1999cited by this paper
• p53 Protein accumulation as a prognostic marker of preoperative radiotherapy and/or chemotherapy in advanced squamous cell esophageal carcinoma--preliminary report.

  1999cited by this paper
• p53 mutations predict non-small cell lung carcinoma response to radiotherapy.

  1999cited by this paper
• Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer

  1999cited by this paper
• The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells

  1999cited by this paper
• The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

  1999cited by this paper
• Usefulness of p53 protein, Bcl-2 protein and Ki-67 as predictors of chemosensitivity of malignant tumors.

  1999cited by this paper
• No significant predictive value of c‐ erbB‐2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

  1998cited by this paper
• p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.

  1998cited by this paper
• Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines.

  1998cited by this paper
• Regulators and mediators of the p53 tumor suppressor.

  1998cited by this paper
• Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation

  1998cited by this paper
• Targeted, non-viral gene delivery for cancer gene therapy.

  1998cited by this paper
• Role of P53 Mutations in the Radiosensitivity Status of Tumor Cells

  1998cited by this paper
• Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer.

  1998cited by this paper
• Association of Loss of Heterozygosity at the p53 Locus with Chemoresistance in Osteosarcomas

  1998cited by this paper
• Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress

  1998cited by this paper
• Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma

  1998cited by this paper
• Radiosensitivity and oxidative signalling in ataxia telangiectasia: an update.

  1998cited by this paper
• Molecular alterations associated with improved survival in pancreatic cancer patients treated with radiation or chemotherapy.

  1998cited by this paper
• The role of p53, p21WAF1/C1PI, and bcl-2 in radioresistant colorectal carcinoma.

  1997cited by this paper
• p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study.

  1997cited by this paper
• ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

  1997cited by this paper
• Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.

  1997cited by this paper
• Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor.

  1997cited by this paper
• p53, the Cellular Gatekeeper Review for Growth and Division

  1997cited by this paper
• Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

  1997influential reference
• Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma.

  1997cited by this paper
• Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts.

  1997cited by this paper
• p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy

  1997cited by this paper
• p53 mutation as a prognostic marker in advanced laryngeal carcinoma. Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group.

  1997cited by this paper
• Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy.

  1997cited by this paper
• Transferrin–Liposome-Mediated p53 Sensitization of Squamous Cell Carcinoma of the Head and Neck to Radiation In Vitro

  1997cited by this paper
• Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy.

  1997cited by this paper
• Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway.

  1996cited by this paper
• p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma.

  1996cited by this paper
• Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation.

  1996cited by this paper
• The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy.

  1996cited by this paper
• p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma

  1996cited by this paper
• Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value.

  1996cited by this paper
• Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein.

  1996cited by this paper
• Manganese superoxide dismutase expression correlates with p53 status and local recurrence of cervical carcinoma treated with radiation therapy.

  1996cited by this paper
• p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma.

  1996cited by this paper
• Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer.

  1996cited by this paper
• Radioresistance and p53 status of T2 laryngeal carcinoma: Analysis by immunohistochemistry and denaturing gradient gel electrophoresis

  1996cited by this paper
• p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas

  1996cited by this paper
• Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.

  1996cited by this paper
• Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma.

  1996cited by this paper
• Increased radiosensitivity is associated with p53 mutations in cell lines derived from oral cavity carcinoma.

  1996cited by this paper
• Targeting DNA to Cells with Basic Fibroblast Growth Factor (FGF2)*

  1996cited by this paper
• p53 Expression: Predicting Recurrence and Second Primary Tumors in Head and Neck Squamous Cell Carcinoma

  1996cited by this paper
• Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.

  1996cited by this paper
• P53 overexpression in head and neck carcinoma and radiotherapy results.

  1996cited by this paper
• Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients.

  1996cited by this paper
• Adenovirus‐mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo

  1996cited by this paper
• p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.

  1996cited by this paper
• The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.

  1996cited by this paper
• Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells.

  1996cited by this paper
• A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.

  1996cited by this paper
• Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer.

  1995cited by this paper
• Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy

  1995cited by this paper
• Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells.

  1995cited by this paper
• Ligand-directed retroviral targeting of human breast cancer cells.

  1995cited by this paper
• p53 expression and the result of adjuvant therapy of breast cancer.

  1995cited by this paper
• Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells.

  1995cited by this paper
• Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck.

  1995cited by this paper
• The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy.

  1995cited by this paper
• Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.

  1995cited by this paper
• Spatial and temporal control of gene therapy using ionizing radiation

  1995cited by this paper
• The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents

  1995cited by this paper
• In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma.

  1995cited by this paper
• Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.

  1995influential reference
• Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy.

  1995cited by this paper
• p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X rays or fission neutrons.

  1995cited by this paper
• Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.

  1995cited by this paper
• Overexpression of p53 Predicts Organ Preservation Using Induction Chemotherapy and Radiation in Patients with Advanced Laryngeal Cancer

  1995cited by this paper
• High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus.

  1994cited by this paper
• Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene.

  1994cited by this paper
• Mutant p53 protein associated with chemosensitivity in breast cancer specimens.

  1994cited by this paper
• Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras.

  1994cited by this paper
• Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer

  1994cited by this paper

• NOSH-aspirin (NBS-1120) inhibits estrogen receptor negative breast cancer in vitro and in vivo by modulating redox-sensitive signaling pathways.

  2024cites this paper
• Oleuropein and its hydrolysate from extra virgin olive oil inhibit breast cancer cells proliferation interfering with the PI3K-AKT signal pathway

  2023cites this paper
• CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor

  2023cites this paper
• RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC

  2022cites this paper
• TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

  2021cites this paper
• Small Molecules Targeting Mutant P53: A Promising Approach For Cancer Treatment.

  2020cites this paper
• Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

  2018cites this paper
• TP53 mutations in peripheral mature T and NK cell lymphomas: a whole-exome sequencing study with correlation to p53 expression.

  2018cites this paper
• Dihydroartemisinin and cisplatinum synergistically induced apoptosis in human lung adenocarcinoma H 1299 cells

  2018cites this paper
• A genome‐wide siRNA screen for regulators of tumor suppressor p53 activity in human non‐small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment

  2017cites this paper
• RIP kinase-mediated ROS production triggers XAF1 expression through activation of TAp73 in casticin-treated bladder cancer cells.

  2016cites this paper
• Molecular mechanisms of drug resistance and its reversal in cancer

  2016cites this paper
• Caspase Activation and Aberrant Cell Growth in a p53+/+ Cell Line from a Li-Fraumeni Syndrome Family

  2015cites this paper
• In Utero Estrogen Exposure Increases Antiestrogen Resistance by Inducing EMT

  2015cites this paper
• Molecular mechanisms of casticin action: an update on its antitumor functions.

  2014cites this paper
• Synthesis of pyrazolo[1,5-a]pyrimidine linked aminobenzothiazole conjugates as potential anticancer agents.

  2013cites this paper
• Casticin induces caspase-mediated apoptosis via activation of mitochondrial pathway and upregulation of DR5 in human lung cancer cells.

  2013cites this paper
• Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status

  2013cites this paper
• Induction of apoptosis by casticin in cervical cancer cells through reactive oxygen species-mediated mitochondrial signaling pathways.

  2011cites this paper
• Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells.

  2011cites this paper
• Synthesis and anticancer activity of oxindole derived imidazo[1,5-a]pyrazines.

  2011cites this paper
• Synthesis and anti breast cancer activity of biphenyl based chalcones.

  2010cites this paper
• ATR mediates cisplatin resistance in a p53 genotype-specific manner

  2010cites this paper
• Is tailored adjuvant treatment for colon cancer possible?

  2010cites this paper
• Glucose deprivation increases nuclear DNA repair protein Ku and resistance to radiation induced oxidative stress in human cancer cells

  2009cites this paper
• Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.

  2008cites this paper
• Profiles of a Novel p 53-Armed Replication-Competent Oncolytic Adenovirus in Rodents , Felids , and Nonhuman Primates

  2008cites this paper
• Anaemia and cancer treatment: a conceptual change.

  2008cites this paper
• p53 gene alterations and human papillomavirus type 16 infection in early stages of cervical carcinoma in Serbia.

  2008cites this paper
• The effect of p53 gene expression on the inhibition of cell proliferation by paclitaxel

  2008cites this paper
• Personalized medicine – p53 gene analysis for prediction of response to neoadjuvant therapy in esophageal cancer

  2008cites this paper
• Targeting the p53/MDM2 Pathway for Cancer Therapy

  2008cites this paper
• Anti-proliferative effects and induction of apoptosis by liquiritigenin in human hepatocellular carcinoma SMMC-7721 cells

  2008cites this paper
• Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates.

  2008cites this paper
• Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.

  2008cites this paper
• Personalized medicine p 53 gene analysis for prediction of response to neoadjuvant therapy in esophageal cancer

  2008cites this paper
• Molecular prognostic markers in locally advanced colon cancer.

  2007cites this paper
• Antitumor activity of a novel bis-aziridinylnaphthoquinone (AZ4) mediating cell cycle arrest and apoptosis in non-small cell lung cancer cell line NCI-H460

  2007cites this paper
• Nitrogen-containing heterocyclic quinones: a class of potential selective antitumor agents.

  2007cites this paper
• The lethal effect of bis-type azridinylnaphthoquinone derivative on oral cancer cells (OEC-M1) associated with anti-apoptotic protein bcl-2.

  2006cites this paper
• Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse.

  2005cites this paper
• Blood Transfusion Requirements for Patients With Sarcomas Undergoing Combined Radio- and Chemotherapy

  2005cites this paper
• Chemotherapy Compounds in Cervical Cancer Cells Primed by Reconstitution of p53 Function after Short Interfering RNA-Mediated Degradation of Human Papillomavirus 18 E6 mRNA: Opposite Effect of siRNA in Combination with Different Drugss⃞

  2005cites this paper
• RNA Interference against Human Papillomavirus Oncogenes in Cervical Cancer Cells Results in Increased Sensitivity to Cisplatin

  2005cites this paper
• A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells

  2004cites this paper
• A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value

  2004cites this paper
• Targeting Vascular and Avascular Compartments of Tumors with C. novyi-NT and Anti-microtubule Agents

  2004cites this paper
• The cytotoxicity of chemotherapy drugs varies in cervical cancer cells depending on the p53 status

  2004cites this paper
• Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway.

  2004cites this paper
• Predicting drug response based on gene expression.

  2004cites this paper
• Clinical applications of genetics in sporadic cancers.

  2004cites this paper
• The p53-dependent apoptotic pathway of breast cancer cells (BC-M1) induced by the bis-type bioreductive compound aziridinylnaphthoquinone

  2004cites this paper
• Cisplatin-induced genes as potential markers for thyroid cancer

  2004cites this paper
• Pharmacogenomics of the p53 tumor suppressor and its role in cancer chemoresistance

  2004cites this paper
• A role for P-glycoprotein in regulating cell growth and survival

  2003cites this paper
• Natural mechanisms protecting against cancer.

  2003cites this paper
• Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein

  2003cites this paper
• Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.

  2003cites this paper
• Antiangiogenic therapy and p53.

  2002cites this paper
• Sensitivity to cisplatin treatment of human K1 thyroid carcinoma cell lines with altered p53 function

  2002cites this paper
• Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand.

  2002cites this paper
• Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells.

  2002cites this paper
• A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance.

  2002cites this paper
• (−)-Epigallocatechin (EGC) of Green Tea Induces Apoptosis of Human Breast Cancer Cells But Not of their Normal Counterparts

  2002cites this paper
• Effect of rhEPO on survival in anaemic cancer patients receiving chemotherapy

  2002cites this paper
• Looking to the Future: Advances in the Management of Hormone-Refractory Prostate Cancer

  2002cites this paper
• DNA-Fragmente im Plasma von Tumorpatienten

  2001cites this paper
• p53 as a drug target in cancer therapy

  2001cites this paper
• The impact of hemoglobin levels on treatment outcomes in patients with cancer.

  2001cites this paper
• Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

  2001cites this paper
• Transferrin-Liposome-Mediated Systemic p53 Gene Therapy in Combination with Radiation Results in Regression of Human Head and Neck Cancer Xenografts

  1999cites this paper